Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

This publication has 10 references indexed in Scilit:

• A Potential Decline in Life Expectancy in the United States in the 21st Century
  New England Journal of Medicine, 2005
• Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
  International Journal of Obesity, 2004
• XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
  Diabetes Care, 2004
• Antagonizing the cannabinoid receptor Type 1: A dual way to fight obesity
  Journal of Endocrinological Investigation, 2003
• The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
  Journal of Clinical Investigation, 2003
• The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells
  Molecular Pharmacology, 2003
• A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding
  Journal of Neuroscience, 2002
• Health consequences of visceral obesity
  Annals of Medicine, 2001
• Effect of sibutramine on weight maintenance after weight loss: a randomised trial
  The Lancet, 2000
• What Is the Economic Case for Treating Obesity?
  Obesity Research, 1998